Literature DB >> 1621634

Surfactant: clinical applications.

C D Patton1, E S Schulman.   

Abstract

Pulmonary surfactant is an important chemical component of the lung. It decreases surface tension in the alveolar cells to help stabilize the alveoli, and it may help prevent pulmonary edema. Currently, naturally and synthetically derived surfactants are being used to treat neonatal respiratory distress syndrome, a leading cause of death in premature infants. Surfactant is recommended for prophylactic therapy in infants weighing less than 1,350 g (3 lb) and in infants weighing more than 1,350 g who show signs of pulmonary immaturity and for rescue therapy in infants with respiratory distress syndrome. Surfactant is administered by endotracheal tube, and the recommended dose is 5 mg per kg. Three doses, given 12 hours apart, is the recommended regimen for prophylactic therapy. Rescue therapy consists of one dose of surfactant given at the onset of respiratory distress and another dose given 12 hours later.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1621634

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  2 in total

Review 1.  Biomechanics of liquid-epithelium interactions in pulmonary airways.

Authors:  Samir N Ghadiali; Donald P Gaver
Journal:  Respir Physiol Neurobiol       Date:  2008-04-22       Impact factor: 1.931

2.  Early surfactant therapy with nasal continuous positive airway pressure or continued mechanical ventilation in very low birth weight neonates with respiratory distress syndrome.

Authors:  Bita Najafian; Seyed Hasan Fakhraie; Seyed Abulfazl Afjeh; Mohammad Kazemian; Majid Shohrati; Amin Saburi
Journal:  Iran Red Crescent Med J       Date:  2014-04-05       Impact factor: 0.611

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.